Justin Taylor: XPO1 Can Be Targeted in TP53-Mutated Myeloid Malignancies
Justin Taylor, Assistant Professor at the UM Sylvester Comprehensive Cancer Center, shared a post on X about recent paper he and colleagues co-authored:
“Super excited to see our collaboration with Eric Padron online in Blood!
Congrats to first author Traci Kruer!
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies.”
Title: XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies
Authors: Traci L Kruer, Ariel Quintana-Gonzalez, Hannah L Newman, Meghan C. Ferrall-Fairbanks, Ling Zhang, Amy F McLemore, Surendra Neupane, Qin Yang, Nana Adjoa Ben-Crentsil, Maria E. Balasis, Christopher T Letson, Rami S Komrokji, Sana Chaudhry, Tulasigeri M Totiger, Joshua A Traina, Maria E Figueroa, Christopher B Ryder, Thomas Cluzeau, Justin Taylor, David A Sallman, Eric Padron
Read The Full Article at Blood.
More posts featuring Justin Taylor on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023